Role of Radioligand Therapy in Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are another major indication for Radioligand Therapy. These tumors often express somatostatin receptors, which can be targeted using radiolabeled somatostatin analogs.
In RLT for NETs, the radioligand binds to somatostatin receptors on tumor cells and delivers therapeutic radiation. This approach allows for treatment of both primary tumors and metastatic disease.
Radioligand Therapy has shown particular benefit in patients with advanced or inoperable neuroendocrine tumors. It provides disease control while preserving quality of life.
The integration of diagnostic imaging and therapy, often referred to as “theranostics,” plays a key role in NET treatment. Imaging confirms receptor expression before therapy, ensuring appropriate patient selection.
This targeted strategy has significantly advanced the management of neuroendocrine tumors.